Oct 22, 2018 7:35am EDT Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors
Oct 17, 2018 7:35am EDT Intensity Therapeutics to Present Preliminary Data from Clinical Study of INT230-6 at Upcoming Medical Conferences
May 31, 2018 7:35am EDT Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO Conference
Feb 27, 2018 7:35am EST Intensity Therapeutics, Inc. Reports Positive Safety Data from Ongoing IT-01 Phase 1/2 Trial
May 30, 2017 7:35am EDT Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial
Apr 04, 2017 7:35am EDT Intensity Therapeutics Reports That INT230-6 Induces Protective T-Cell Immunity in Preclinical Models
Jun 28, 2016 7:35am EDT Intensity Therapeutics, Inc. Raises $10 Million to Fund Clinical Supplies Manufacturing and Phase I/II Trials of INT230-6
